ARMO BioSciences Announces Pricing of Initial Public Offering ARMO BioSciences, Inc. (“ARMO”), a late-stage immuno-oncology company, today announced the pricing of its initial public offering of 7,529,412 shares of its common stock at a price to the public of $17.00 per share for … Continued
ARMO BioSciences Presents Efficacy Data from its Phase 1b Trial in Patients with Metastatic Renal Cell Carcinoma at ESMO ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced additional clinical trial results on its lead investigational immuno-oncology drug AM0010 (pegilodecakin) … Continued
ARMO BioSciences Appoints Herb Cross as Chief Financial Officer ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the appointment of Herb Cross as Chief Financial Officer, a newly-created position. Mr. Cross has over twenty years of experience, with executive leadership roles … Continued
Making DNA Storage a Reality In the late 1970s, a bizarre theory began making its way around the scientific community. DNA sequencing pioneer Frederick Sanger of the Medical Research Council’s Laboratory of Molecular Biology and his colleagues had just … Continued
Twist Bioscience and Collaborators Microsoft, University of Washington Preserve Archive-Quality Audio Recordings for Memory of the World Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that, working with Microsoft and University of Washington … Continued
TowerJazz and Crocus Expand Presence in Magnetic Sensors Market through Successful Licensing of Crocus’ IP and Volume Manufacturing by TowerJazz TowerJazz, the global specialty foundry leader, and Crocus, a leading developer of TMR magnetic sensor technology and embedded MRAM, … Continued
Congratulations to Armon (Young Innovator of the Year) and Amy (Newcomer of the Year) on winning their categories at the first annual Xconomy Awards! Check out all the winners here!
ARMO BioSciences’s Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival in Patients with Advanced Pancreatic Cancer, NSCLC, and RCC ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced that clinical trial results on its lead investigational immuno-oncology … Continued
6 ‘Change the World’ Companies That Are Rising Stars Big ideas sometimes come in little packages, and plenty of smaller businesses have a big influence on their communities, their customers, and the planet. Our Rising Stars list honors companies … Continued
ARMO BioSciences Raises $67 Million in a Series C-1 Financing ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the successful completion of a $67 million Series C-1 private financing led by new investor Qiming Venture Partners’ U.S. Healthcare Fund. Additional new … Continued